Loxo Oncology to Present Updated LOXO-101 Phase 1 Data at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Loxo Oncology to Present Updated LOXO-101 Phase 1 Data at the 2016 AACR Annual Meeting

– Company to Host Investor Conference Call and Webcast on Monday, April 18, 2016 –

STAMFORD, Conn., April 11, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the abstract titled "Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions" has been accepted for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 16 – 20, 2016 in New Orleans. Data from this trial were most recently presented at the AACR-NCI-EORTC meeting in November 2015.  The presentation will include an efficacy and durability update for enrolled patients with TRK fusions. The presentation was selected for inclusion in AACR’s official press program, and study data will therefore remain embargoed until April 17, 2016 at 4:15 p.m. CT.

The schedule for the oral presentation is as follows:

Oral Presentation Date & Time:  April 17, 2016,   4:15 p.m. to 6:00 p.m. CT Title:  Clinical Safety and Activity from a Phase 1 Study of LOXO-101, a Selective TRKA/B/C Inhibitor, in Solid Tumor Patients with NTRK Gene Fusions Abstract Number: CT008 Session Title:  Precision Medicine Early Clinical Trials Presenter:  David Hong, M.D., deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Location:  La Nouvelle Orleans Ballroom, Morial Convention Center

Conference Call and Webcast Information

Loxo Oncology will host a conference call and live webcast on Monday, April 18, 2016 at 8:00 a.m. Eastern Time to discuss the LOXO-101 data. To participate in the conference call, please dial (877) 930-8065 (domestic) or (253) 336-8041 (international) and refer to conference ID 77038770. A live webcast of the presentation will be available at http://ir.loxooncology.com/ . A replay of the webcast will be available shortly after the conclusion of the call and archived on the company's website for 30 days following the call.

About LOXO-101

LOXO-101 is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. In an ongoing Phase 1 clinical trial, LOXO-101 has demonstrated encouraging preliminary efficacy. LOXO-101 is also being evaluated in a global Phase 2 multi-center basket trial in patients with solid tumors that harbor TRK gene fusions. For additional information about both the LOXO-101 clinical trials, please refer to www.clinicaltrials.gov . Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com . 

Forward Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding the timing and success of our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Annual Report on Form 10-K, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts for Loxo Oncology, Inc.  Company: Jacob S. Van Naarden Chief Business Officer jake@loxooncology.com  

Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com  

Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com   

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 86

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 72

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading

Top 5 Most Recently Viewed Articles

AI Adoption Challenges Identify Risks in Asian Financial Sector

Updated Category News Views 141

Understanding the AI Adoption Gap in Asian Financial Institutions The landscape of financial institutions in Asia is undergoing significant scrutiny as the adoption of artificial intelligence (AI) remains slow. Despite the clear advantages that AI can provide—particularly in the realm of financial crime prevention—many Asian financial institutions still lag behind...

Continue Reading
Reykjavík Energy's Successful Green Bond Auction Highlights

Updated Category News Views 170

Reykjavík Energy's Green Bond Auction Overview Recently, Reykjavík Energy (Orkuveita Reykjavíkur; OR) successfully completed its latest green bond auction, revealing a positive reception from investors. With total bids reaching ISK 7,785 million nominal value across various bond classes, the auction showcased a robust interest in sustainable finance opportunities....

Continue Reading
SpaceX Rescues Stranded NASA Astronauts from ISS

Updated Category News Views 293

SpaceX Conducts Heroic Rescue Mission for NASA Astronauts SpaceX recently embarked on a significant mission, launching a Crew Dragon spaceship designed to rescue two stranded astronauts in space. This mission exemplifies the advancements and capabilities of private space exploration. Details of the Rescue Operation Typically, the Crew Dragon is built to carry a crew of...

Continue Reading
Legal Action for Investors of Warner Bros. Discovery: WBD Update

Updated Category News Views 93

Understanding the Warner Bros. Discovery Class Action Lawsuit Warner Bros. Discovery, Inc. (NASDAQ: WBD) is currently facing a class action securities lawsuit that aims to assist investors who have suffered financial losses. This lawsuit has been initiated by Levi & Korsinsky, LLP, a renowned firm specializing in securities litigation. What is the Class Definition? The...

Continue Reading
Revolutionary Intruder Detainment System Enhances Home Security

Updated Category News Views 105

Revolutionary Intruder Detainment System for Improved Safety In today's world, home security is a top priority, making innovative safety solutions essential. A creative individual from Chicago has developed an exciting detainment system designed to bolster security measures. This new invention, called HELP, can capture intruders in real-time and hold them until law...

Continue Reading